These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 27242888)

  • 1. The Use of DREADDs to Deconstruct Behavior.
    Whissell PD; Tohyama S; Martin LJ
    Front Genet; 2016; 7():70. PubMed ID: 27242888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility.
    Urban DJ; Roth BL
    Annu Rev Pharmacol Toxicol; 2015; 55():399-417. PubMed ID: 25292433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of chemogenetics in behavioural neuroscience: receptor variants, targeting approaches and caveats.
    Campbell EJ; Marchant NJ
    Br J Pharmacol; 2018 Apr; 175(7):994-1003. PubMed ID: 29338070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemogenetics drives paradigm change in the investigation of behavioral circuits and neural mechanisms underlying drug action.
    Ozawa A; Arakawa H
    Behav Brain Res; 2021 May; 406():113234. PubMed ID: 33741409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DREADDS: Use and application in behavioral neuroscience.
    Smith KS; Bucci DJ; Luikart BW; Mahler SV
    Behav Neurosci; 2016 Apr; 130(2):137-55. PubMed ID: 26913540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.
    Chen X; Choo H; Huang XP; Yang X; Stone O; Roth BL; Jin J
    ACS Chem Neurosci; 2015 Mar; 6(3):476-84. PubMed ID: 25587888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dreadds: Use and application in behavioral neuroscience.
    Smith KS; Bucci DJ; Luikart BW; Mahler SV
    Behav Neurosci; 2021 Apr; 135(2):89-107. PubMed ID: 34060867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resolving Behavioral Output via Chemogenetic Designer Receptors Exclusively Activated by Designer Drugs.
    Burnett CJ; Krashes MJ
    J Neurosci; 2016 Sep; 36(36):9268-82. PubMed ID: 27605603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studying brain-regulation of immunity with optogenetics and chemogenetics; A new experimental platform.
    Ben-Shaanan T; Schiller M; Rolls A
    Brain Behav Immun; 2017 Oct; 65():1-8. PubMed ID: 27890661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resting-State fMRI-Based Screening of Deschloroclozapine in Rhesus Macaques Predicts Dosage-Dependent Behavioral Effects.
    Fujimoto A; Elorette C; Fredericks JM; Fujimoto SH; Fleysher L; Rudebeck PH; Russ BE
    J Neurosci; 2022 Jul; 42(29):5705-5716. PubMed ID: 35701162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemogenetic Signaling in Space and Time: Considerations for Designing Neuroscience Experiments Using DREADDs.
    Clark PJ; Brodnik ZD; España RA
    Neuroscientist; 2024 Jun; 30(3):328-346. PubMed ID: 36408535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.
    Gomez JL; Bonaventura J; Lesniak W; Mathews WB; Sysa-Shah P; Rodriguez LA; Ellis RJ; Richie CT; Harvey BK; Dannals RF; Pomper MG; Bonci A; Michaelides M
    Science; 2017 Aug; 357(6350):503-507. PubMed ID: 28774929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Behavioral Manipulation via Orally Delivered Chemogenetic Actuator in Macaques.
    Oyama K; Hori Y; Nagai Y; Miyakawa N; Mimura K; Hirabayashi T; Inoue KI; Takada M; Higuchi M; Minamimoto T
    J Neurosci; 2022 Mar; 42(12):2552-2561. PubMed ID: 35110390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral Effect of Chemogenetic Inhibition Is Directly Related to Receptor Transduction Levels in Rhesus Monkeys.
    Upright NA; Brookshire SW; Schnebelen W; Damatac CG; Hof PR; Browning PGF; Croxson PL; Rudebeck PH; Baxter MG
    J Neurosci; 2018 Sep; 38(37):7969-7975. PubMed ID: 30082415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DREADDs for Neuroscientists.
    Roth BL
    Neuron; 2016 Feb; 89(4):683-94. PubMed ID: 26889809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemogenetic modulation of astrocytes and microglia: State-of-the-art and implications in neuroscience.
    Bossuyt J; Van Den Herrewegen Y; Nestor L; Buckinx A; De Bundel D; Smolders I
    Glia; 2023 Sep; 71(9):2071-2095. PubMed ID: 37222453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical Considerations for the Use of DREADD and Other Chemogenetic Receptors to Regulate Neuronal Activity in the Mammalian Brain.
    Aldrin-Kirk P; Björklund T
    Methods Mol Biol; 2019; 1937():59-87. PubMed ID: 30706390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice.
    Zhu H; Aryal DK; Olsen RH; Urban DJ; Swearingen A; Forbes S; Roth BL; Hochgeschwender U
    Genesis; 2016 Aug; 54(8):439-46. PubMed ID: 27194399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis for selective activation of DREADD-based chemogenetics.
    Zhang S; Gumpper RH; Huang XP; Liu Y; Krumm BE; Cao C; Fay JF; Roth BL
    Nature; 2022 Dec; 612(7939):354-362. PubMed ID: 36450989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative assessment of the effects of DREADDs and endogenously expressed GPCRs in hippocampal astrocytes on synaptic activity and memory.
    Lee SH; Mak A; Verheijen MHG
    Front Cell Neurosci; 2023; 17():1159756. PubMed ID: 37051110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.